

10th International Chicago Lymphoma Symposium April 26-27, 2013

Speaker Evaluation

1. Dissecting Diffuse Large B-Cell Lymphoma: Why Does it Matter?

	5	4	3	2	1	Rating Average	Rating Count
Georg Lenz, MD	69.5% (41)	25.4% (15)	3.4% (2)	1.7% (1)	0.0% (0)	4.63	59

COMMENTS: 5

answered question	59
skipped question	12

2. The Genetics of Lymphoma

	5	4	3	2	1	Rating Average	Rating Count
Adam Bagg, MD	81.7% (49)	15.0% (9)	3.3% (2)	0.0% (0)	0.0% (0)	4.78	60

COMMENTS: 5

answered question	60
skipped question	11

3. The Biology of B Cell Transformation

	5	4	3	2	1	Rating Average	Rating Count
Laura Pasqualucci, MD	50.0% (30)	33.3% (20)	11.7% (7)	5.0% (3)	0.0% (0)	4.28	60

COMMENTS: 10

answered question	60
skipped question	11

4. PI3K/Akt/mTOR Inhibitors in Lymphoma: Predicting Response and Outcome

	5	4	3	2	1	Rating Average	Rating Count
Adam M. Petrich, MD	41.0% (25)	44.3% (27)	14.8% (9)	0.0% (0)	0.0% (0)	4.26	61

COMMENTS: 4

answered question	61
skipped question	10

5. Integrating Novel Therapies into the Management of Cutaneous T Cell Lymphomas

	5	4	3	2	1	Rating Average	Rating Count
Professor H. Miles Prince, MBBS MD	71.2% (42)	23.7% (14)	5.1% (3)	0.0% (0)	0.0% (0)	4.66	59

COMMENTS: 7

answered question	59
skipped question	12

6. Emerging Immunotherapies for the Treatment of B Cell Malignancies

	5	4	3	2	1	Rating Average	Rating Count
Oliver W. Press, MD, PhD	86.9% (53)	9.8% (6)	3.3% (2)	0.0% (0)	0.0% (0)	4.84	61

COMMENTS: 6

answered question	61
skipped question	10

7. FCR Should be in the Stanford Front-Line Therapy for Most Patients with CLL

	5	4	3	2	1	Rating Average	Rating Count
Alessandra Ferrajoli, MD (PRO)	70.6% (48)	23.5% (16)	5.9% (4)	0.0% (0)	0.0% (0)	4.65	68
Tait D. Shanafell, MD (CON)	86.6% (58)	13.4% (9)	0.0% (0)	0.0% (0)	0.0% (0)	4.87	67
Moderator: Stephanie A. Gregory, MD	79.7% (51)	15.6% (10)	3.1% (2)	1.6% (1)	0.0% (0)	4.73	64

COMMENTS: 13

answered question	68
skipped question	3

8. Non-Transplant Options in Mantle Cell Lymphoma: Who, When and Why?

	5	4	3	2	1	Rating Average	Rating Count
Michael E. Williams, MD, ScM	77.9% (53)	19.1% (13)	2.9% (2)	0.0% (0)	0.0% (0)	4.75	68

COMMENTS: 4

answered question	68
skipped question	3

9. Primary Mediastinal Lymphoma: Update on Management

	5	4	3	2	1	Rating Average	Rating Count
Jane N. Winter, MD	74.3% (52)	21.4% (15)	4.3% (3)	0.0% (0)	0.0% (0)	4.70	70

COMMENTS: 4

answered question	70
skipped question	1

10. PCNSL: A Practical Approach

	5	4	3	2	1	Rating Average	Rating Count
James L. Rubenstein, PhD, MD	60.9% (42)	31.9% (22)	7.2% (5)	0.0% (0)	0.0% (0)	4.54	69

COMMENTS: 7

answered question	69
skipped question	2

11. State of the Art: Staging, Restaging and Response Evaluation in Lymphoma

	5	4	3	2	1	Rating Average	Rating Count
Bruce D. Cheson, MD	91.2% (62)	8.8% (6)	0.0% (0)	0.0% (0)	0.0% (0)	4.91	68

COMMENTS: 13

answered question	68
skipped question	3

12. Clinical Cases/Expert Panel

	5	4	3	2	1	Rating Average	Rating Count
Sonali M. Smith, MD	78.8% (52)	16.7% (11)	4.5% (3)	0.0% (0)	0.0% (0)	4.74	66
Panel	50.0% (1)	50.0% (1)	0.0% (0)	0.0% (0)	0.0% (0)	4.50	2

COMMENTS: 6

answered question	66
skipped question	5

13. Optimal Front-Line Treatment In FL

	5	4	3	2	1	Rating Average	Rating Count
Andrew M. Evens, DO, MSc	75.8% (47)	16.1% (10)	8.1% (5)	0.0% (0)	0.0% (0)	4.68	62

COMMENTS: 4

answered question	62
skipped question	9

14. Timing of Stem Cell Transplantation in FL

	5	4	3	2	1	Rating Average	Rating Count
Timothy S. Fenske, MD	66.0% (35)	30.2% (16)	3.8% (2)	0.0% (0)	0.0% (0)	4.62	53

COMMENTS:

1

answered question	53
skipped question	18

Page 1, Q1. Dissecting Diffuse Large B-Cell Lymphoma: Why Does it Matter?

1	Very technical, (illegible). Very good!	Jun 11, 2013 12:30 PM
2	Could not hear, did not talk (illegible)	Jun 11, 2013 11:45 AM
3	Spoke fast- knew his topic	Jun 11, 2013 11:32 AM
4	I didn't attend the April 26 day	Jun 10, 2013 3:36 PM
5	Being a NP in oncology - This was over my head. Did not address R side of room - was harder to hear because he directed his voice+attention to L wall slides - slides too busy - too small to read on handout. Very hard to follow. Spoke fast without explaining to the range of attendees.	Jun 10, 2013 3:14 PM

Page 1, Q2. The Genetics of Lymphoma

1	Great lecture, great style!	Jun 11, 2013 12:50 PM
2	Very technical, (illegible). Very good!	Jun 11, 2013 12:30 PM
3	Could not hear, not (illegible)	Jun 11, 2013 11:45 AM
4	Very in depth	Jun 11, 2013 11:32 AM
5	Good speaker. Did well directing his attention to both sides of the room also could hear well.	Jun 10, 2013 3:14 PM

Page 1, Q3. The Biology of B Cell Transformation

1	Little too basic + off topic to me	Jun 11, 2013 1:24 PM
2	Didn't talk about the biology of transformation	Jun 11, 2013 1:13 PM
3	A complex talk	Jun 11, 2013 1:01 PM
4	Seemed very interesting - Sorry, difficult to understand	Jun 11, 2013 12:55 PM
5	Very technical, (illegible). Very good! (illegible) to understand.	Jun 11, 2013 12:30 PM
6	Too complex	Jun 11, 2013 12:25 PM
7	Could not hear, not (illegible)	Jun 11, 2013 11:45 AM
8	Too many experimental details crammed into a short talk.	Jun 10, 2013 3:48 PM
9	Great presentation, very thorough	Jun 10, 2013 3:22 PM
10	Accent strong - hard to understand @ times/ over my head. Used good eye contact+hearing was good - slides too busy - too small on slides and handouts	Jun 10, 2013 3:14 PM

Page 1, Q4. PI3K/Akt/mTOR Inhibitors in Lymphoma: Predicting Response and Outcome

1	Confusing -all over the place	Jun 11, 2013 11:45 AM
2	Great talk. Honest and thought-provoking.	Jun 10, 2013 3:48 PM
3	Very easy to follow	Jun 10, 2013 3:22 PM
4	Good speaker - good eye contact	Jun 10, 2013 3:14 PM

Page 1, Q5. Integrating Novel Therapies into the Management of Cutaneous T Cell Lymphomas

1	May want to take out "midget" slide	Jun 11, 2013 12:57 PM
2	Excellent	Jun 11, 2013 12:44 PM
3	Very good	Jun 11, 2013 12:30 PM
4	Too long	Jun 11, 2013 12:21 PM
5	Outstanding talk.	Jun 10, 2013 3:48 PM
6	Nice pictures. Great talk - some slides are too small (font)	Jun 10, 2013 3:22 PM
7	Good eye contact. Nice accent - slides too busy - hard to read	Jun 10, 2013 3:14 PM

Page 1, Q6. Emerging Immunotherapies for the Treatment of B Cell Malignancies

1	Wow!	Jun 11, 2013 12:25 PM
2	Excellent!	Jun 11, 2013 12:21 PM
3	Great	Jun 11, 2013 12:05 PM
4	Great!	Jun 11, 2013 11:55 AM
5	Excellent speaker	Jun 11, 2013 11:32 AM
6	Great. Good eye contact/ addressed both sides of the room. Easy to hear - gave information and studies that were understandable. Best talk of the day - great use of humor.	Jun 10, 2013 3:14 PM

Page 2, Q1. FCR Should be in the Stanford Front-Line Therapy for Most Patients with CLL

1	Thank you for a great discussion & good look @ the pros and cons of the treatments on this disease + pt population.	Jun 11, 2013 12:53 PM
2	Very well done	Jun 11, 2013 12:44 PM
3	Dr. Shanafell - Excellent talk, very well spoken	Jun 11, 2013 12:42 PM
4	Dr. Ferrajoli and Dr. Shanafell, both good and practical	Jun 11, 2013 12:35 PM
5	Dr. Ferrajoli was difficult to understand	Jun 11, 2013 12:26 PM
6	Fun	Jun 11, 2013 12:22 PM
7	Excellent!	Jun 11, 2013 12:02 PM
8	Couldn't hear Ferrajoli and understand	Jun 11, 2013 11:47 AM
9	Hard to understand Dr. Ferrajoli	Jun 11, 2013 11:33 AM
10	Dr. Ferrajoli was hard to hear	Jun 11, 2013 11:30 AM
11	Dr. Ferrajoli's presentation was good but she did not debate the point! She gave an overview. Did not argue the point with other studies.	Jun 10, 2013 3:50 PM
12	Slides too busy - hard to see/read	Jun 10, 2013 3:18 PM
13	Great format	Jun 10, 2013 3:05 PM

Page 2, Q2. Non-Transplant Options in Mantle Cell Lymphoma: Who, When and Why?

1	More coffee	Jun 11, 2013 1:24 PM
2	Invite him back - wonderful!	Jun 11, 2013 12:44 PM
3	Practical, lots (illegible)	Jun 11, 2013 12:35 PM
4	Excellent	Jun 11, 2013 12:22 PM

Page 2, Q3. Primary Mediastinal Lymphoma: Update on Management

1	Great speaker	Jun 11, 2013 12:42 PM
2	Excellent (illegible)	Jun 11, 2013 12:35 PM
3	Good review	Jun 11, 2013 12:22 PM
4	Good speaker	Jun 10, 2013 3:18 PM

Page 2, Q4. PCNSL: A Practical Approach

1	Talk was very good, but too long. If going to present (illegible) take more time	Jun 11, 2013 1:19 PM
2	Newer data	Jun 11, 2013 12:35 PM
3	Spoke to long	Jun 11, 2013 12:24 PM
4	Great	Jun 11, 2013 12:06 PM
5	Good content, but presenter talked too fast	Jun 11, 2013 12:02 PM
6	Too long	Jun 11, 2013 11:57 AM
7	Slides were good/easy to read most of the time. Did not address the right side of the group. Some references were too old - more than 10 years.	Jun 10, 2013 3:18 PM

Page 2, Q5. State of the Art: Staging, Restaging and Response Evaluation in Lymphoma

1	Excellent discussion	Jun 11, 2013 12:55 PM
2	Very good info & discussion. Thank you. Let's decrease over scanning	Jun 11, 2013 12:53 PM
3	Excellent talk, great speaker	Jun 11, 2013 12:42 PM
4	Excellent counseling on PET/CT	Jun 11, 2013 12:35 PM
5	Exellent	Jun 11, 2013 12:26 PM
6	Excellent talk!	Jun 11, 2013 12:24 PM
7	In a class of his own!	Jun 11, 2013 12:22 PM
8	Great	Jun 11, 2013 12:06 PM
9	Excellent!	Jun 11, 2013 12:02 PM
10	Excellent	Jun 11, 2013 11:51 AM
11	Great presentation	Jun 11, 2013 11:33 AM
12	Superb	Jun 10, 2013 3:20 PM
13	Good	Jun 10, 2013 3:18 PM

Page 2, Q6. Clinical Cases/Expert Panel

1	To few cases	Jun 11, 2013 12:24 PM
2	Excellent review on exteneous lymphomas	Jun 11, 2013 12:22 PM
3	Interesting, but somewhat redundant as information was reviewed elsewhere in the symposium.	Jun 11, 2013 12:02 PM
4	Excellent	Jun 11, 2013 11:51 AM
5	Excellent presentation	Jun 10, 2013 3:24 PM
6	Likes this presentation/ more case studies like this should be considered	Jun 10, 2013 3:18 PM

Page 2, Q7. Optimal Front-Line Treatment In FL

1	Nice job!	Jun 11, 2013 12:53 PM
2	!	Jun 11, 2013 12:06 PM
3	Excellent	Jun 10, 2013 3:31 PM
4	Very good speaker (lots of information lots of studies/would have liked more of his professional practice.	Jun 10, 2013 3:18 PM

Page 2, Q8. Timing of Stem Cell Transplantation in FL

1	Great pics!	Jun 11, 2013 12:26 PM
---	-------------	-----------------------